logo-loader
viewMaxCyte Inc

MaxCyte agrees clinical and commercial deal with US t-cell therapy expert

Caribou Biosciences will use MaxCyte’s flow electroporation systems and the company’s ExPERT platform

MaxCyte Inc -
Pictured are t-cells attacking a cancer cell

MaxCyte Inc (LON:MXCT) has signed a clinical and commercial agreement with a US life sciences group for its cutting edge gene-editing technology.

Caribou Biosciences will use MaxCyte’s flow electroporation systems and the company’s ExPERT platform in its allogeneic t-cell therapy programmes.

MaxCyte will receive undisclosed development and approval milestones as well as sales-based payments and “other licensing fees”.

“This important agreement represents another key expansion for MaxCyte, emphasising the value of our technology platform to companies developing pioneering gene-editing and cell therapies,” MaxCyte’s chief executive, Doug Doerfler said in a statement.

“We believe that such programs have high potential to deliver positive clinical impact for patients facing serious and difficult-to-treat diseases."

MaxCyte describes its Flow Electroporation system as being able to deliver “virtually any molecule, to any cell, at any scale”.

Its ExPERT instrument family set takes this a step forward by allowing scientists to carry out complex cell engineering.

Quick facts: MaxCyte Inc

Price: 310 GBX

AIM:MXCT
Market: AIM
Market Cap: £239.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read